KRAS Vaccine Shows Promise in Intercepting Pancreatic Cancer
TL;DR Summary
Phase I trial of the KRAS-targeting vaccine mKRAS-VAX in 20 high‑risk individuals with pancreatic abnormalities showed 90% developed a robust immune response against six KRAS mutations, with memory cells detectable up to two years; no pancreatic cancer or high‑risk lesions developed during a median follow‑up of 16.5 months, and some precursor cysts regressed, supporting larger trials to test cancer interception.
- Pancreatic Cancer Vaccine Triggers Immune Response Before Tumors Develop Inside Precision Medicine
- Sandra Misale: Intercepting PDAC in High-risk Individuals by KRAS-Targeting Vaccine Oncodaily
- From Treatment to Prevention: How Vaccines Are Reshaping the Fight Against Pancreatic Cancer American Association for Cancer Research (AACR)
- Johns Hopkins-Developed KRAS Vaccine Shows Durable Immune Response in Pancreatic Cancer Prevention Trial BioPharm International
- Could A Vaccine Prevent Pancreatic Cancer In Those At High Risk? U.S. News & World Report
Reading Insights
Total Reads
1
Unique Readers
4
Time Saved
7 min
vs 8 min read
Condensed
96%
1,527 → 60 words
Want the full story? Read the original article
Read on Inside Precision Medicine